Axsome Therapeutics (AXSM) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
8 Jul, 2026Strategic focus and growth trajectory
Maintains a core focus on CNS disorders, with openness to synergistic opportunities outside neuroscience if strategically justified.
Employee count has grown from under 100 to over 1,000 in five years, reflecting rapid scaling.
Projects significant evolution by 2031, driven by a robust pipeline and expanding indications.
Ownership mentality and data-driven investment guide long-term strategy.
Product portfolio and recent approvals
Three marketed products: AUVELITY (recently approved for Alzheimer's disease agitation), SYMBRAVO (migraine), and SUNOSI (excessive daytime sleepiness in OSA and narcolepsy).
AUVELITY's differentiated mechanism and strong efficacy/safety profile support its use in both MDD and ADA.
AUVELITY label highlights rapid onset, durable effect, and minimal adverse reactions.
Peak sales guidance for AUVELITY raised to $8 billion, driven by label advantages, market share growth, and payer coverage.
Commercial strategy and market access
Sales force expanded from 160 to over 600 reps, enabling deeper and more frequent HCP engagement.
Commercial launch for ADA is on track, with sales reps trained to detail both MDD and ADA.
Market access strategy aims for unrestricted coverage; current payer coverage at 86% of total lives.
Long-term care facilities targeted for the first time, leveraging synergies between MDD and ADA.
Latest events from Axsome Therapeutics
- AUVELITY momentum and an expanded pipeline underpin the next phase of growth.AXSM
UBS Global Biopharma Conference 2026 - AUVELITY momentum and a deep pipeline frame a $260M-revenue quarter.AXSM
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 52% as AUVELITY-led sales narrowed losses and pipeline milestones advanced.AXSM
Q3 2026 - Auvelity’s launch and pipeline expansion underpin an expected next phase of growth.AXSM
H.C. Wainwright 28th Annual Global Investment Conference - AUVELITY's growth accelerates in new indications, with strong pipeline and financial outlook.AXSM
Morgan Stanley 24th Annual Global Healthcare Conference - AUVELITY's commercial expansion and deep pipeline position the company for strong near-term growth.AXSM
12th Annual Cantor Fitzgerald Global Healthcare Conference - AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials.AXSM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue grew 46% to $218.4M, led by AUVELITY's Alzheimer's launch and pipeline progress.AXSM
Q2 2026 - Late-stage CNS pipeline targets high unmet needs with strong data and major commercial potential.AXSM
R&D Day 2025 - Symbravo gains FDA approval for acute migraine, offering rapid, sustained relief and broad market potential.AXSM
FDA Announcement